[go: up one dir, main page]

WO2008012635A3 - Amine derivatives useful as anticancer agents - Google Patents

Amine derivatives useful as anticancer agents Download PDF

Info

Publication number
WO2008012635A3
WO2008012635A3 PCT/IB2007/002065 IB2007002065W WO2008012635A3 WO 2008012635 A3 WO2008012635 A3 WO 2008012635A3 IB 2007002065 W IB2007002065 W IB 2007002065W WO 2008012635 A3 WO2008012635 A3 WO 2008012635A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compounds
anticancer agents
amine derivatives
derivatives useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/002065
Other languages
French (fr)
Other versions
WO2008012635A2 (en
Inventor
Matthew Stephen Corbett
Goss Stryker Kauffman
Kevin Daniel Freeman-Cook
Blaise Scott Lippa
Michael Joseph Luzzio
Joel Morris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of WO2008012635A2 publication Critical patent/WO2008012635A2/en
Publication of WO2008012635A3 publication Critical patent/WO2008012635A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates to compounds of formula (I), or a pharmaceutically acceptable salt thereof, wherein: A is a moiety of formula (II), and to pharmaceutically acceptable salts and solvates thereof. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula I to a patient in need thereof, and to compositions for treating such disorders which contain the compounds of formula (I). The invention also relates to methods of making the compounds of formula (I).
PCT/IB2007/002065 2006-07-26 2007-07-13 Amine derivatives useful as anticancer agents Ceased WO2008012635A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82044106P 2006-07-26 2006-07-26
US60/820,441 2006-07-26

Publications (2)

Publication Number Publication Date
WO2008012635A2 WO2008012635A2 (en) 2008-01-31
WO2008012635A3 true WO2008012635A3 (en) 2008-05-08

Family

ID=38963178

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/002065 Ceased WO2008012635A2 (en) 2006-07-26 2007-07-13 Amine derivatives useful as anticancer agents

Country Status (7)

Country Link
AR (1) AR062050A1 (en)
CL (1) CL2007002188A1 (en)
GT (1) GT200700062A (en)
PE (1) PE20080689A1 (en)
TW (1) TW200817408A (en)
UY (1) UY30499A1 (en)
WO (1) WO2008012635A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9303040B2 (en) 2006-07-06 2016-04-05 Array Biopharma Inc. Substituted piperazines as AKT inhibitors

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2049500T1 (en) 2006-07-06 2012-01-31 Array Biopharma Inc CYCLOPENTA ?áD?å PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
UA99284C2 (en) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані P70 s6 kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
MX2009014013A (en) 2007-07-05 2010-01-28 Array Biopharma Inc Pyrimidyl cyclopentanes as akt protein kinase inhibitors.
NZ582692A (en) 2007-07-05 2012-05-25 Array Biopharma Inc Pyrimidyl cyclopentanes as akt protein kinase inhibitors
WO2009089352A1 (en) 2008-01-08 2009-07-16 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
ES2422733T3 (en) 2008-01-09 2013-09-13 Array Biopharma Inc Hydroxylated pyrimidylcyclopentanes as AKT protein kinase inhibitors
AU2009204019B2 (en) 2008-01-09 2014-02-20 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
ES2392014T3 (en) 2008-01-09 2012-12-03 Array Biopharma, Inc. Pyrazolopyridines as kinase inhibitors
CL2009001152A1 (en) 2008-05-13 2009-10-16 Array Biopharma Inc Compounds derived from n- (4- (nitrogen cycloalkyl-1-yl) -1h-pyrrolo [2,3-b] pyridin-3-yl) amide, kinase inhibitors; Preparation process; pharmaceutical composition; and its use for the treatment of a proliferative disease.
AU2013218743B2 (en) * 2008-05-13 2016-04-28 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
AR074072A1 (en) 2008-11-11 2010-12-22 Lilly Co Eli COMPOSITE OF IMIDAZOL -PIPERIDIN -PIRROL-PIRIMIDIN-6-ONA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT MULTIFORM GLIOBLASTOMA
TW201035100A (en) 2008-12-19 2010-10-01 Cephalon Inc Pyrrolotriazines as ALK and JAK2 inhibitors
DE102009005193A1 (en) * 2009-01-20 2010-07-22 Merck Patent Gmbh Novel heterocyclic compounds as MetAP-2 inhibitors
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
US8846673B2 (en) 2009-08-11 2014-09-30 Bristol-Myers Squibb Company Azaindazoles as kinase inhibitors and use thereof
US8785440B2 (en) 2009-09-04 2014-07-22 Biogen Idec Ma, Inc. Bruton's tyrosine kinase inhibitors
US8343977B2 (en) 2009-12-30 2013-01-01 Arqule, Inc. Substituted triazolo-pyrimidine compounds
CN103442710B (en) 2010-11-16 2018-05-29 阵列生物制药公司 Combinations of Checkpoint Kinase 1 Inhibitors and WEE1 Kinase Inhibitors
WO2012080735A1 (en) 2010-12-16 2012-06-21 Convergence Pharmaceuticals Limited Ask1 inhibiting pyrrolopyrimidine derivatives
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2012135779A1 (en) 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt and mek inhibitor compounds, and methods of use
BR112013025353A8 (en) 2011-04-01 2018-01-02 Genentech Inc combination of a) a compound of formula ia, compound of formula ia or a pharmaceutically acceptable salt thereof, method for treating a hyperproliferative disorder in a mammal, use of a compound of formula ia or a pharmaceutically acceptable salt thereof, kit and product
MX347241B (en) * 2011-09-12 2017-04-20 Merck Patent Gmbh Aminopyrimidine derivatives for use as modulators of kinase activity.
AR091273A1 (en) 2012-06-08 2015-01-21 Biogen Idec Inc PYRIMIDINYL TIROSINE KINASE INHIBITORS
UA125503C2 (en) 2012-06-13 2022-04-13 Інсайт Холдинґс Корпорейшн Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
WO2014172644A2 (en) 2013-04-19 2014-10-23 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
UA121669C2 (en) 2015-02-20 2020-07-10 Інсайт Корпорейшн BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
UA123785C2 (en) 2016-03-28 2021-06-02 Інсайт Корпорейшн PYROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS
CN110049976A (en) 2016-07-21 2019-07-23 比奥根Ma公司 The succinate form and composition of bruton's tyrosine kinase inhibitor
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN112566912A (en) 2018-05-04 2021-03-26 因赛特公司 Salts of FGFR inhibitors
SI3788047T1 (en) 2018-05-04 2024-11-29 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4045151A1 (en) 2019-10-14 2022-08-24 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4069695A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Derivatives of an fgfr inhibitor
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022272062A1 (en) 2021-06-24 2022-12-29 Reservoir Neuroscience, Inc. Ep2 antagonist compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065909A1 (en) * 1998-06-19 1999-12-23 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO2006046024A1 (en) * 2004-10-25 2006-05-04 Astex Therapeutics Limited Ortho- condensed pyridine and pyrimidine derivatives (e. g. purines) as protein kinases inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065909A1 (en) * 1998-06-19 1999-12-23 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO2006046024A1 (en) * 2004-10-25 2006-05-04 Astex Therapeutics Limited Ortho- condensed pyridine and pyrimidine derivatives (e. g. purines) as protein kinases inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9303040B2 (en) 2006-07-06 2016-04-05 Array Biopharma Inc. Substituted piperazines as AKT inhibitors

Also Published As

Publication number Publication date
AR062050A1 (en) 2008-08-10
WO2008012635A2 (en) 2008-01-31
CL2007002188A1 (en) 2008-02-01
UY30499A1 (en) 2008-02-29
PE20080689A1 (en) 2008-06-14
GT200700062A (en) 2008-08-08
TW200817408A (en) 2008-04-16

Similar Documents

Publication Publication Date Title
WO2008012635A3 (en) Amine derivatives useful as anticancer agents
WO2006067614A3 (en) Heteroaromatic derivatives useful as anticancer agents
WO2009155121A3 (en) Inhibitors of pi3 kinase
WO2007138472A3 (en) Triazolopyridazine derivatives
TW200728307A (en) Novel spirochromanone derivatives
EA200870423A1 (en) DERIVATIVES OF TRIAZOLPYRAZINES APPLICABLE AS ANTI-CANCER AGENTS
WO2008019967A3 (en) Phenyl, pyridine and quinoline derivatives
UA89123C2 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
TW200833675A (en) Nicotinamide derivatives
WO2006053342A3 (en) Integrin antagonists useful as anticancer agents
UA99361C2 (en) TRIAZINE COMPOUNDS AS PI3 KINASE AND mTOR INHIBITORS
MX2009004096A (en) Talarazole metabolites.
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
WO2007135527A3 (en) Benzimidazolyl compounds
MX2009009238A (en) Novel phosphodi esterase inhibitors.
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
WO2007126900A3 (en) Antifungal agents
MX2008002061A (en) Thiazolyl piperidine derivatives.
NO20083708L (en) 4-Phenyl-thiazole-5-carboxylic acid and 4-phenyl-thiazole-5-carboxylmides as PLK1 inhibitors
WO2006116733A3 (en) Protein kinase inhibitors
TW200745066A (en) Novel PTP1B inhibitors
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
TW200716547A (en) Piperidin-4-yl-amide derivatives
TW200626158A (en) Naphthaline derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07789508

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07789508

Country of ref document: EP

Kind code of ref document: A2